The combination therapy of atezolizumab (an anti-PDL1 mono­ clonal antibody (mAb)) plus bevacizumab (an anti-vascular endothelial growth factor (VEGF) mAb) represents a new milestone in the field of HCC treatment (15, 16). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.